Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson’s disease in patients already taking ropinirole immediate-release tablets (Requip®) and in whom adequate symptomatic control has been established. Substitution of ropinirole prolonged-release tablets for ropinirole immediate-release may be used as: (i) Monotherapy, alone (without levodopa) in idiopathic Parkinson’s disease. (ii) Adjunctive therapy in addition to levodopa to control ‘on-off’ fluctuations which might permit a reduction in the total daily dose of levodopa. In order to limit errors, prolonged-release ropinirole should be prescribed by brand as Requip XL®. AWMSG is of the opinion that prolonged-release ropinirole (Requip XL®) may be suitable for shared care in accordance with appropriate guidance.